Eculizumab for atypical hemolytic-uremic syndrome in India: First report from India and the challenges faced

Much progress has been made in understanding the pathophysiology and treatment of atypical hemolytic uremic syndrome (aHUS). Plasma therapy is the mainstay of treatment for aHUS. The availability of the first effective anti-complement therapeutic agent, eculizumab, has dramatically changed the outlo...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Indian J Nephrol
Main Authors: Sethi, S. K., Rohatgi, S., Dragon-Durey, M. A., Raghunathan, V., Dhaliwal, M., Rawat, A., Jha, P., Bansal, S. B., Raina, R., Kher, V.
Format: Artigo
Jezik:Inglês
Izdano: Medknow Publications & Media Pvt Ltd 2017
Teme:
Case Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5255992/
https://ncbi.nlm.nih.gov/pubmed/28182046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0971-4065.179369
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki